Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (120)
  2. Journal Article (86)
  3. Review (5)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (215)
  2. Department of Medicine (215)
  3. Solid Tumor Oncology Division (215)
  4. GSK Faculty (58)
  5. Survivorship Research (45)
  6. Epidemiology and Biostatistics (44)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (28)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (21)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (9)
  5. European Journal of Cancer (5)
  6. Oncology Research and Treatment (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (46)
  3. Oxford University Press (23)
  4. Elsevier Inc. (16)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (215)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study
    Meeting Abstract

    Hamilton, E. P.; De Laurentiis, M.; Jhaveri, K. L.; Hu, X.; Ladoire, S.; Patsouris, A.; Zamagni, C.; Cui, J.; Cazzaniga, M.; Cil, T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Comparative analysis of PIK3CA mutation detection methods in the first-in-human phase 1/1b study of inavolisib
    Meeting Abstract

    Hilz, S.; Accordino, M. K.; Bedard, P.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Jhaveri, K. L.; Juric, D.; Kalinsky, K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Opinions of real-world clinicians on endocrine resistance in HR+/HER2-mBC: Results from the RETRACT survey of US oncologists
    Meeting Abstract

    Gradishar, W. J.; Hamilton, E. P.; Mahtani, R. L.; Hurvitz, S. A.; Jhaveri, K. L.; Tolaney, S. M.; Rugo, H. S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Opinions of real-world clinicians regarding visceral crisis in HR+/HER2-mBC: Results from the RETRACT survey of US oncologists
    Meeting Abstract

    Jhaveri, K. L.; Gradishar, W. J.; Hamilton, E. P.; Hurvitz, S. A.; Mahtani, R. L.; Tolaney, S. M.; Rugo, H. S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns, genomic characteristics, and outcomes among patients with metastatic lobular breast cancer
    Meeting Abstract

    Shen, S.; Pareja, F.; White, C.; Chen, Y.; Safonov, A.; Razavi, P.; Dang, C. T.; Jhaveri, K. L.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer
    Meeting Abstract

    Mai, N.; Liu, B.; Safonov, A.; Shen, S.; Zelizer, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.; Modi, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns in HR+/HER2-metastatic breast cancer (MBC) with co-occurring PIK3CA and ESR1 mutations
    Meeting Abstract

    Teysir, J.; Shen, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial
    Meeting Abstract

    Curigliano, G.; O'Shaughnessy, J.; Bidard, F. C.; Kim, S. B.; Tokunaga, E.; Aftimos, P. G.; Manich, C. S.; Carey, L. A.; Okera, M.; Melo, É.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)
    Meeting Abstract

    Turner, N. C.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; Shankar, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
    Meeting Abstract

    Oliveira, M.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Jhaveri, K. L.; Juric, D.; Kalinsky, K.; Krop, I. E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save